Among different IBD treatments, vedolizumab is associated with an increased risk of SARS-CoV-2 infection compared to mesalazine but did not significantly differ from anti-TNF regarding combined outcomes of SARS-CoV-2-related hospitalization and mortality in a retrospective cohort study of 30,911 IBD patients [80]. This evidence concerns the gene TNF and inflammatory bowel disease.